Transcode Therapeutics Inc is a biotechnology business based in the US. TransCode Therapeutics shares (RNAZ) are listed on the NASDAQ and all prices are listed in US Dollars. TransCode Therapeutics employs 8 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Active traders
| Latest market close | $1.16 |
|---|---|
| 52-week range | $0.98 - $3.46 |
| 50-day moving average | $1.23 |
| 200-day moving average | $1.96 |
| Wall St. target price | $10.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.55 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.16 from 2022-10-04
| 1 week (2022-09-28) | 4.50% |
|---|---|
| 1 month (2022-09-06) | 14.85% |
| 3 months (2022-07-06) | -10.08% |
| 6 months (2022-04-06) | -59.01% |
| 1 year (2021-10-06) | -55.04% |
|---|---|
| 2 years (2020-10-02) | N/A |
| 3 years (2019-10-02) | N/A |
| 5 years (2017-10-02) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -107.88% |
| Return on equity TTM | -359.04% |
| Profit margin | 0% |
| Book value | $0.96 |
| Market capitalisation | $14.3 million |
TTM: trailing 12 months
We're not expecting TransCode Therapeutics to pay a dividend over the next 12 months.
TransCode Therapeutics, Inc. , a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNA"based agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9"based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts. .
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
Here are the best renewable energy stocks that should be on your radar to help you grow your green portfolio
Here are 6 manganese stocks that should be on your radar as EV batteries create new demand.
Our list of 10 dividend stocks to watch in 2022.
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.